Saltar al contenido
Merck

A0200000

Acetylsalicylic acid

European Pharmacopoeia (EP) Reference Standard

Sinónimos:

2-Acetoxybenzoic acid, O-Acetylsalicylic acid, ASA, Aspirin

Iniciar sesión para ver los precios por organización y contrato.

Seleccione un Tamaño

Cambiar Vistas

Acerca de este artículo

Fórmula lineal:
2-(CH3CO2)C6H4CO2H
Número CAS:
Peso molecular:
180.16
UNSPSC Code:
41116107
NACRES:
NA.24
PubChem Substance ID:
MDL number:
Beilstein/REAXYS Number:
779271
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarle


grade

pharmaceutical primary standard

API family

aspirin

manufacturer/tradename

EDQM

mp

134-136 °C (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

CC(=O)Oc1ccccc1C(O)=O

InChI

1S/C9H8O4/c1-6(10)13-8-5-3-2-4-7(8)9(11)12/h2-5H,1H3,(H,11,12)

InChI key

BSYNRYMUTXBXSQ-UHFFFAOYSA-N

Gene Information

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Acetylsalicylic acid EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Blocks the production of prostaglandins by inhibiting cyclooxygenase (prostaglandin H synthase), with greater selectivity toward the COX-1 isoform. The antithrombotic effect is due to the inhibition of COX-1 in platelets that blocks thromboxane production and platelet aggregation. Chemopreventive against colorectal and other solid tumors.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.


Still not finding the right product?

Explore all of our products under Acetylsalicylic acid


pictograms

Exclamation mark

signalword

Warning

Clase de almacenamiento

11 - Combustible Solids

wgk

WGK 1

flash_point_f

482.0 °F

flash_point_c

250 °C

hcodes

Hazard Classifications

Acute Tox. 4 Oral - Aquatic Chronic 3



Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documentos section.

Si necesita más asistencia, póngase en contacto con Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos



Christina Perneby et al.
Thrombosis and haemostasis, 95(4), 652-658 (2006-04-08)
Aspirin is widely used, but dosages in different clinical situations and the possible importance of "aspirin resistance" are debated. We performed an open cross-over study comparing no treatment (baseline) with three aspirin dosage regimens--37.5 mg/day for 10 days, 320 mg/day
Andrew O Maree et al.
Journal of the American College of Cardiology, 46(7), 1258-1263 (2005-10-04)
We investigated whether use of low-dose enteric-coated (EC) aspirin for secondary prevention of cardiovascular events has sufficient bioavailability to achieve complete platelet cyclooxygenase (COX) inhibition in all individuals. Aspirin reduces cardiovascular morbidity and mortality in patients with pre-existing vascular disease;
A O Maree et al.
Journal of thrombosis and haemostasis : JTH, 3(10), 2340-2345 (2005-09-10)
Aspirin (acetylsalicylic acid) irreversibly inhibits platelet cyclooxygenase (COX)-1, the enzyme that converts arachidonic acid (AA) to the potent platelet agonist thromboxane (TX) A2. Despite clear benefit from aspirin in patients with cardiovascular disease (CAD), evidence of heterogeneity in the way